Compare Davita Inc (DVA) vs Lam Research Corporation (LRCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Lam Research Corporation — how do they compare? Davita Inc trades at $179.56 (market cap $11.29B), while Lam Research Corporation trades at $322.3 (market cap $401.19B). The key difference: Lam Research Corporation is far larger — about 35.5× Davita Inc's market cap, and Lam Research Corporation pays a 0.41% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Lam Research Corporation for 60 Days on average.
| DVA | LRCX | |
|---|---|---|
Market Cap | $11.29B | $401.19B |
Volume | 582,204 | 8,960,892 |
Sector | Health | Technology |
52-Week High | $240.96 | $433.33 |
52-Week Low | $103.87 | $131.37 |
Typical Hold Time | 113 Days | 60 Days |
Enterprise Value | $24.01B | $399.35B |
Dividend Yield | — | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, with a bearish technical signal and neutral oscillators. The company shows strong earnings beats in recent quarters with Q2 2026 EPS of $4.02 beating expectations of $3.88. Revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026, though net margins have fluctuated. Recent partnership expansion with Humana for value-based kidney care represents significant business development.
DVA presents a mixed outlook with 43% analyst buy ratings and a $235.67 price target suggesting 33% upside. However, high debt levels (65.55% debt-to-asset ratio) and regulatory risks in healthcare weigh on fundamentals. The stock's current valuation at P/E 15 and P/S 0.88 appears reasonable relative to earnings growth potential, making it attractive for value investors despite near-term bearish technicals.
Lam Research (LRCX) trades at $329.51, down 1.31% on the day, amid strong fundamental performance with revenue growth to $18.44B in 2025 and net income of $5.36B. The stock shows bullish technical signals with moving averages supporting upward momentum, while RSI levels indicate mixed short-term sentiment. Recent earnings beats and a consensus analyst price target of $375.68 suggest potential upside, supported by AI-driven demand for semiconductor equipment.
Outlook remains positive with expanding profit margins and robust cash flow, though valuation multiples like P/E of 55.66 pose risks if growth slows. Key opportunities include AI infrastructure spending and operational efficiency, while risks involve semiconductor cycle volatility and competitive pressures. Institutional sentiment is strongly bullish with 78% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Lam Research Corporation
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →
